Arprinocid

Arprinocid

Arprinocid is an antiprotozoal agent that is used in veterinary medicine to treat coccidiosis, a parasitic disease affecting a variety of animals. It is a derivative of quinolone and is specifically effective against the protozoa Eimeria species, which are responsible for causing coccidiosis.

History

Arprinocid was first synthesized in the 1970s by the pharmaceutical industry as a potential treatment for coccidiosis. It was found to be highly effective in controlling the disease in poultry, particularly chickens and turkeys.

Mechanism of Action

Arprinocid works by inhibiting the DNA gyrase enzyme in the protozoa, preventing the replication of the parasite's DNA and thus stopping its growth and reproduction. This mechanism of action is similar to that of other quinolone derivatives.

Usage

Arprinocid is administered orally, usually mixed with feed, to animals suspected of having coccidiosis. The dosage and duration of treatment depend on the severity of the infection and the species of animal being treated.

Side Effects

Like all medications, arprinocid can cause side effects. These may include loss of appetite, vomiting, and diarrhea. In rare cases, it can cause more serious side effects such as liver damage or neurological disorders.

Regulatory Status

Arprinocid is approved for use in several countries, including the United States, where it is regulated by the Food and Drug Administration (FDA). However, it is not approved for use in all countries, and its use is prohibited in some due to concerns about potential drug resistance and environmental impact.

See Also

• Antiprotozoal agent
• Coccidiosis
• Quinolone
• Eimeria
• DNA gyrase
• Food and Drug Administration

‎